688189 南新制药
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)-1.708-15.917-30.937-1.631-5.725
总资产报酬率 ROA (%)-1.659-13.475-23.557-1.161-3.794
投入资产回报率 ROIC (%)-1.678-14.006-24.736-1.213-4.024

边际利润分析
销售毛利率 (%)25.21431.50352.50583.33785.788
营业利润率 (%)-57.985-93.413-149.416-3.248-10.287
息税前利润/营业总收入 (%)-58.591-93.470-150.223-2.457-9.585
净利润/营业总收入 (%)-56.817-105.515-153.075-3.470-13.743

收益指标分析
经营活动净收益/利润总额(%)78.77460.15020.442-144.933-53.804
价值变动净收益/利润总额(%)0.0000.0000.00070.7007.775
营业外收支净额/利润总额(%)0.0210.1260.152-0.9250.755

偿债能力分析
流动比率 (X)4.2314.2752.2902.9432.308
速动比率 (X)3.7563.8922.1102.8732.266
资产负债率 (%)11.72011.99128.15125.40733.676
带息债务/全部投入资本 (%)1.4761.16618.78420.44729.321
股东权益/带息债务 (%)6,647.3778,436.399430.395387.338239.254
股东权益/负债合计 (%)832.095807.263272.160298.084199.680
利息保障倍数 (X)98.701-1,548.718259.234-3.226-12.285

营运能力分析
应收账款周转天数 (天)113.455293.768512.185339.717339.337
存货周转天数 (天)180.309179.680137.81094.579160.282